GLN-APREMILAST

glenmark pharmaceuticals canada inc.🇨🇦 Health Canada

Approval Id: bb8f46c575a27521
Drug Approval Canada Name: GLN-APREMILAST
Product Name: GLN-APREMILAST
Status: Marketed
Status Date: 2022-11-14
Original Market Date: 2022-11-14
Din: 02518910
Drug Class: Human
Dosage Form: Tablet
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 90:24.24.92
Atc Original: L04AA32 APREMILAST
Atc Name: l 04 aa 32
Aig Number: 0156231002
Company Name: glenmark pharmaceuticals canada inc.
Company Address: 1600 Steeles Ave. W., Suite 407, Concord, Ontario, Canada, L4K 4M2

APREMILAST

30 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

bb8f46c575a27521

Type

Standard